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INTRODUCTION

CASE DESCRIPTION

Background:
Immunotherapy, in conjunction with
chemotherapy and radiation, represents an
essential modality in the strive towards
individualized cancer therapy such as
treatment with pembrolizumab. However, it
does not come without its side effects.

Chief Complaint:
fatigue, indigestion and weight loss
History of Present Illness:
70 yof with pmhx of tobacco use disorder and
metastatic pulmonary adenocarcinoma s/p
chemotherapy with pemetrexed (d/c’d d/t
repeated afib and renal dysfxn), palliative
radiation and currently undergoing
immunotherapy w/ pembrolizumab q3wks that
presents to outpatient infusion center w/ fatigue,
poor appetite and weight loss found to have a
random repeat CBG of 686.

Pembrolizumab (Keytruda):
Mechanism of Action:
Highly selective anti-PD-1 humanized
monoclonal antibody which inhibits
programmed cell death-1 (PD-1) activity by
binding to PD-1 receptor on T-cells to block
PD-1 ligands (PD0-L1 and PD-L2) from
binding. Blocking the PD-1 pathway inhibits
the negative immune regulation caused by
PD-1 receptor signaling. Anti-PD-1 antibodies
(including pembrolizumab) reverse T-cell
suppression and induce antitumor
responses.2

Management:
New onset T1DM w/ hyperglycemia
- Likely d/t rare autoimmune side effect from
immunotherapy
- No e/o DKA (no AG)
- IV fluids for initial volume resuscitation
- Start weight-based insulin regimen with close
follow up
- Nutritionist
- Screening for other autoimmune conditions;
TSH, ACTH stim test

Indications:
Melanoma, breast cancer, endometrial
carcinoma, metastatic non-small cell lung
cancer, esophageal and gastric cancer,
urothelial carcinoma

DISCUSSION
Immunotherapy with Pembrolizumab:
- anti-PD-1 therapy not specific towards cancer
cells
- Normal, non-cancerous cells, if affected
cannot inhibit T-cells from immune response
and subsequent cell death
- Unknown mechanisms but likely through
destruction of beta islet cells
- Previous literature review in 2018 showing six
reported cases of autoimmune diabetes
associated with pembrolizumab w/o sexual
predilection and avg age onset 58 years old.3
- 4 of those cases initially presented with
diabetic ketoacidosis
- No association between number of treatments
and onset.
- Variation from normal to elevated A1c seen
- Of cases reviewed, 5 out of 6 had to continue
insulin therapy, likely irreversible
- Use of steroid for treatment has not been
established (has been used for other immune
toxicities associated with pembrolizumab)

KEY LEARNING POINTS
• Pembrolizumab can induce autoimmune
conditions; including Type 1 Diabetes
• While receiving pembrolizumab therapy,
periodic CBG checks can prevent DKA and
associated morbidity and mortality
• Treatment includes insulin therapy (steroids
not yet indicated)
• Pembrolizumab induced diabetes not likely
reversible
• Screen patient for other autoimmune
conditions; TSH and ACTH

Adverse Reactions:
Arrhythmias, peripheral edema, pruritus, rash,
abdominal pain, fatigue, headache,
hypothyroidism, colitis, hepatitis
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